94 related articles for article (PubMed ID: 9780151)
1. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.
Isaacs JD; Greenwood J; Waldmann H
J Immunol; 1998 Oct; 161(8):3862-9. PubMed ID: 9780151
[TBL] [Abstract][Full Text] [Related]
2. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
3. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.
Scallon B; McCarthy S; Radewonuk J; Cai A; Naso M; Raju TS; Capocasale R
Int Immunopharmacol; 2007 Jun; 7(6):761-72. PubMed ID: 17466910
[TBL] [Abstract][Full Text] [Related]
4. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
[TBL] [Abstract][Full Text] [Related]
5. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.
Smith RI; Coloma MJ; Morrison SL
J Immunol; 1995 Mar; 154(5):2226-36. PubMed ID: 7868896
[TBL] [Abstract][Full Text] [Related]
6. Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.
Rajnavölgyi E; Fazekas G; Lund J; Daeron M; Teillaud JL; Jefferis R; Fridman WH; Gergely J
Immunology; 1995 Apr; 84(4):645-52. PubMed ID: 7540592
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
8. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
Isaacs JD; Clark MR; Greenwood J; Waldmann H
J Immunol; 1992 May; 148(10):3062-71. PubMed ID: 1578132
[TBL] [Abstract][Full Text] [Related]
9. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences.
Sibéril S; Dutertre CA; Boix C; Bonnin E; Ménez R; Stura E; Jorieux S; Fridman WH; Teillaud JL
Immunol Lett; 2006 Aug; 106(2):111-8. PubMed ID: 16797726
[TBL] [Abstract][Full Text] [Related]
10. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.
Lund J; Takahashi N; Pound JD; Goodall M; Jefferis R
J Immunol; 1996 Dec; 157(11):4963-9. PubMed ID: 8943402
[TBL] [Abstract][Full Text] [Related]
11. Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors.
Ding JW; Zhou T; Zeng H; Ma L; Verbeek JS; Yin D; Shen J; Chong AS
J Immunol; 2008 Jan; 180(1):261-8. PubMed ID: 18097027
[TBL] [Abstract][Full Text] [Related]
12. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
13. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
14. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation.
Liu D; Ren D; Huang H; Dankberg J; Rosenfeld R; Cocco MJ; Li L; Brems DN; Remmele RL
Biochemistry; 2008 May; 47(18):5088-100. PubMed ID: 18407665
[TBL] [Abstract][Full Text] [Related]
15. Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.
Chin LT; Chu C; Chen HM; Hsu SC; Weng BC; Chu CH
BMC Biotechnol; 2007 Aug; 7():51. PubMed ID: 17714596
[TBL] [Abstract][Full Text] [Related]
16. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
Arduin E; Arora S; Bamert PR; Kuiper T; Popp S; Geisse S; Grau R; Calzascia T; Zenke G; Kovarik J
Mol Immunol; 2015 Feb; 63(2):456-63. PubMed ID: 25451975
[TBL] [Abstract][Full Text] [Related]
17. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
18. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency.
Scallon B; Cai A; Radewonuk J; Naso M
Mol Immunol; 2004 May; 41(1):73-80. PubMed ID: 15140577
[TBL] [Abstract][Full Text] [Related]
19. Structural motifs involved in human IgG antibody effector functions.
Greenwood J; Clark M; Waldmann H
Eur J Immunol; 1993 May; 23(5):1098-104. PubMed ID: 8477804
[TBL] [Abstract][Full Text] [Related]
20. [Regulation of Fc receptor expression by immune complexes on neutrophils and U937 cells].
Guo LH; Zhang W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):510-4. PubMed ID: 15562762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
